FindTrial
Sign In

remifentanil requirements during liver transplantation

The influence of the severity of liver disease on remifentanil requirements during liver transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0002870
Enrollment
40
Registered
2018-05-16
Start date
2018-05-17
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Samsung Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: from 20 to 70 yr old recipients who undergo liver transplantation at Samsung Medical Center

Exclusion criteria

Exclusion criteria: Patient refused Patients with arrhythmia (SPI measurement is less accurate) Patients with remifentanil allergy

Design outcomes

Primary

MeasureTime frame
The comparison of amount of remifentanil used in patients with median modified end liver disease score(MELD); low v.s high—

Secondary

MeasureTime frame
Factors affecting SPI values (volume status-pulse pressure variation, pulmonary artery wedge pressure, end diastolic volume);The comparison of amount of remifentanil used is determined by dissection-anhepatic-reperfusion phase;The nociception level to surgical incision was evaluated by heart rate, blood pressure, and SPI—

Countries

Korea, Republic of

Contacts

Public ContactMiHye Park

Samsung Medical Center

dukiduck@gmail.com+82-2-3410-6575

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026